Tom van Meerten - Concepedia

Author

Tom van Meerten

University Medical Center Groningen ORCID

Also Known As

Hubert van Hoogstraten, Liu, Xiaodong, T van Meerten, T. Van Meerten, T. van Meerten, Tom Van Meerten, Tom van Meerten, van Meerten, Tom

196

Publications

5.8K

Citations

H-Index

Concepts

All Affiliations

University Medical Center Groningen University of Groningen University Medical Center Utrecht University of Amsterdam Amsterdam University Medical Centers

About

Tom van Meerten is an author at University Medical Center Groningen specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	229
2	Immunology	8	8	229
3	Health Sciences	3	3	103
4	Cell Biology	3	3	85
5	Cellular Therapies	1	1	21

Tom van Meerten

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma Frederick L. Locke, David B. Miklos, Caron A. Jacobson, New England Journal of Medicine	2021	1.4K
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 Jessica L. Teeling, Wendy J.M. Mackus, Luus Wiegman, The Journal of Immunology	2006	599
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten, New England Journal of Medicine	2023	359
Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells Keisuke Watanabe, Seitaro Terakura, Anton C. Martens, The Journal of Immunology	2014	280
Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity Tom van Meerten, Rozemarijn S. van Rijn, Samantha Hol, Clinical Cancer Research	2006	242
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma Olalekan O. Oluwole, Krimo Bouabdallah, Javier Muñoz, British Journal of Haematology	2021	195
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma Max S. Topp, Tom van Meerten, Roch Houot, British Journal of Haematology	2021	112
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network Martin Dreyling, Jeanette K. Doorduijn, Eva Giné, The Lancet	2024	104
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19 Sabine Haggenburg, Quincy Hofsink, Birgit I. Lissenberg‐Witte, JAMA Oncology	2022	81
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma Gloria Iacoboni, Kai Rejeski, Guillermo Villacampa, Blood Advances	2022	77

Page 1